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Chronic obstructive pulmonary disease (COPD) is
one of themost common causes of death worldwide.
We report in an emphysema model of mice chro-
nically exposed to tobacco smoke that pulmonary
vascular dysfunction, vascular remodeling, and pul-
monary hypertension (PH) precede development
of alveolar destruction. We provide evidence for a
causative role of inducible nitric oxide synthase
(iNOS) and peroxynitrite in this context. Mice lacking
iNOS were protected against emphysema and PH.
Treatment of wild-type mice with the iNOS inhibitor
N6-(1-iminoethyl)-L-lysine (L-NIL) prevented struc-
tural and functional alterations of both the lung
vasculature and alveoli and also reversed estab-
lished disease. In chimeric mice lacking iNOS in
bone marrow (BM)-derived cells, PH was dependent
on iNOS from BM-derived cells, whereas emphy-
sema development was dependent on iNOS from
non-BM-derived cells. Similar regulatory and struc-
tural alterations as seen in mouse lungs were found
in lung tissue from humans with end-stage COPD.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD), which includes
both chronic bronchitis and emphysema, is expected to be
ranked as the third-greatest cause of death worldwide by 2020
(Murray and Lopez, 1997). One pathological concept suggests
that COPD develops through airway inflammation and remodel-
ing. The main theory behind emphysema development is the
destruction of the elastic architecture of the lung, leading to
enlargement of distal air spaces (Black et al., 2008). Moreover,COPD/emphysema is increasingly viewed as a systemic dis-
ease, involving skeletal muscle wasting, diaphragmatic dysfunc-
tion, and systemic inflammation (Agustı´ et al., 2003).
An estimated 30%–70% of patients with COPD also have
pulmonary hypertension (PH); however, there is much debate
about the numbers of patients affected by PH, and many
patients with COPD have no severe PH (Minai et al., 2010).
Thus, the relevance of a vascular pathology for the pathogenesis
of COPD is still unresolved. PH was often thought to occur as
a consequence of the hypoxia associated with COPD, but there
is increasing evidence that tobacco smoke may have a direct
impact on the pulmonary vasculature (Peinado et al., 2008), indi-
cating that cor pulmonale and late-stage PH are not necessarily
secondary to hypoxia in patients with COPD. These data are
supported by studies in guinea pigs, showing that a vascular
phenotype can precede parameters of emphysema develop-
ment (Ferrer et al., 2009; Wright and Churg, 1990, 1991). How-
ever, to the best of our knowledge, no published study directly
compares the course of emphysema development and PH in
other species.
Oxidative and nitrosative stress, chronic inflammation, apo-
ptosis, and altered proliferation have been suggested as factors
in the pathogenesis of airway remodeling (Churg et al., 2008; Ric-
ciardolo et al., 2004; Stockley et al., 2009; Tsoumakidou et al.,
2005). This has led to attention being focused on the involvement
of interleukins, the vascular endothelial-derived growth factor
(VEGF) system, matrix metalloproteinases (Mmp), and reactive
oxygen species (ROS) (Taraseviciene-Stewart and Voelkel,
2008; Yoshida and Tuder, 2007) in destroying the lung architec-
ture. ROS and reactive nitrogen species have long been known
to cause protein modification and DNA damage (Wink and
Mitchell, 1998). Indeed, nitric oxide (NO) reacts with superoxide
(O2
,) to form the potent oxidant peroxynitrite (ONOO) (Szabo´
et al., 2007); this in turn can react with tyrosine residues to
form nitrotyrosine, the levels of which are increased in COPD
(Ricciardolo et al., 2004; Tsoumakidou et al., 2005).Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 293
NO is synthesized from L-arginine by nitric oxide synthase
(NOS), which exists as three isoforms (Moncada and Erusalim-
sky, 2002). Increased NO production and nitrosative stress in
COPD may derive from enhanced expression or activity of
inducible NOS (iNOS) and endothelial NOS (eNOS) (Brindicci
et al., 2009). However, the regulation of NOS isoforms during
the course of emphysema development has not yet been
addressed.
In order to investigate the molecular mechanisms involved in
disease progression as a basis to develop new strategies to treat
COPD, we aimed to (1) decipher the role of NOS in the develop-
ment of emphysema and examine possible vascular alterations
leading to PH after tobacco-smoke exposure and (2) investigate
a possible link between vascular alterations and emphysema
development.
RESULTS
Pulmonary Hypertension Precedes Lung Emphysema
Development in Wild-Type Mice Exposed to Tobacco
Smoke
Exposure of wild-type (WT) mice to tobacco smoke for up to
8 months resulted in the development of lung emphysema after
6 months, as evident from an increase in the mean linear inter-
cept, an increase in the air space, and a decrease in the septal
wall thickness (Figures 1A–1C).
Within 3 months, tobacco-smoke exposure caused increases
in right ventricular systolic pressure and the ratio of the absolute
numbers of alveoli to the number of vessels, followed by right-
heart hypertrophy (Figures 1D–1F): i.e., development of PH
preceded the development of lung emphysema. PH was associ-
ated with an increase in the degree of muscularization in the
pulmonary arteries (diameter 20–70 mm) (Figures 1G and 1H). A
similar increase in the degree of muscularization was found in
larger pulmonary arteries (data not shown). The late onset of
lung emphysema development compared with the development
of PHwas also evident from lung-function data (Figure S1A avail-
able online). PH occurred, althoughmice did not suffer from alve-
olar hypoxia or hypoxemia (Figure S1Bi, ii), despite substantial
carbon monoxide (CO) generation during tobacco-smoke expo-
sure (Figure S1Biii, iv) previously shown to antagonize PH (Zuck-
erbraun et al., 2006). In addition, the loss of vessels seen in the
tobacco-smoke-induced emphysema model was unparalleled
in hypoxia-induced PH, although the vascular phenotype was
comparable (Figure S1C). We also observed that gene regulation
was different in hypoxia than in tobacco-smoke-induced PH
(Figure S1D).
Effects of Tobacco Smoke on iNOS and eNOS
Expression in the Pulmonary Vasculature
of Wild-Type Mice
We examined eNOS and iNOS expression during the course of
tobacco-smoke exposure. Immunofluorescence staining sug-
gested an upregulation of the iNOS protein, being more promi-
nent in the pulmonary vasculature compared to alveolar septa
or bronchi in smoke-exposed mice (Figure 2A). In situ hybridiza-
tion mirrored these results and suggested some upregulation of
iNOS mRNA in bronchi; however, this was not confirmed by the294 Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc.quantitativemRNA analysis frombronchi and alveolar septa (Fig-
ure 2B). By contrast, immunofluorescence staining and in situ
hybridization suggested a downregulation of eNOS in the pulmo-
nary vasculature, with some transient upregulationwithin the first
3 months of smoke exposure (Figure 2A). These data were
confirmed by quantitative polymerase chain reaction (PCR) analy-
sis of pulmonary vessels (diameter 50–100 mm), alveolar septa,
and bronchi (diameter 140–300 mm) and by western blotting
from homogenized lung tissue (Figures 2B and 2C). Expression
of iNOS and eNOS could mostly, but not exclusively, be allocated
to cells expressing a-smooth muscle actin by in situ hybridization
(data not shown). iNOS upregulation was mirrored by an increase
in iNOS activity in the lung but not in bronchoalveolar lavage (BAL)
cells (Figure S2).
Mice Deficient in iNOS Are Protected against the
Development of PH, Emphysema, and Functional
Alterations Caused by Tobacco-Smoke Exposure
We compared the development of PH and emphysema after
8 months of tobacco-smoke exposure in iNOS/, eNOS/,
and WT mice. The iNOS/ mice were protected against the
development of emphysema and PH, as evident from quantifica-
tion of (1) mean linear intercept, air space, septal wall thickness
(Figures 3A–3C); (2) right ventricular systolic pressure, the ratio of
alveoli/vessels, right-heart hypertrophy (Figures 3D–3F); and (3)
the degree of muscularization (Figure 3G). By contrast, eNOS/
mice developed emphysema and PH to the same degree as WT
controls (Figures 3A–3G). Similar patterns were also seen in
lung-function parameters (Figure S3A).
iNOS Inhibition Prevented Smoke-Induced Functional
Deterioration and Reversed Deterioration of Fully
Established Emphysema
Treatment of WT mice with the iNOS-selective inhibitor L-NIL
was started in parallel to smoke exposure and resulted in protec-
tion against the development of lung emphysema, as shown
by alveolar morphometry (Figures 3H–3J), and against PH, as
shown by hemodynamic measurements and morphometry
(Figures 3K–3N). These findings were mirrored by lung-function
parameters (Figure S3B).
Lung structure and function were restored when WT mice
were treated with L-NIL in a curative approach after full estab-
lishment of emphysema (i.e., initiation of L-NIL treatment after
8 months of chronic smoke exposure for an additional 3 month
period) (Figures 3H–3N). Lung regeneration did not occur in
placebo-treated animals. Analysis of lungs from a second, inde-
pendent set of curatively L-NIL-treated mice revealed (besides
effects on cellular components; Figures S3C and S3D) that the
number of alveoli (assessed by stereological morphometry,
which excludes lung-volume-dependent effects) was signifi-
cantly reduced after 8 months of smoke exposure and restored
by curative L-NIL treatment but not by placebo treatment (Fig-
ure 4Ai). In vivo lung-function assessment from these animals re-
vealed an increase in lung dynamic compliance after 8 months of
smoke exposure, which was reversed upon curative L-NIL treat-
ment but not with placebo (Figure 4Aii). The reversal effect of
L-NIL treatment was also evident for PH (Figure 4Aiii). Detailed
investigation and quantification of elastic-fiber structure by light,
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Figure 1. TimeCourse of the Development of Emphysema and Pulmonary Hypertension during Tobacco-Smoke Exposure inWild-TypeMice
(A–C) Alveolar morphometry given as (A) mean linear intercept, (B) air space, and (C) septal wall thickness.
(D) Right ventricular systolic pressure.
(E) Ratio of the number of alveoli to the number of vessels per area.
(F) Right-heart hypertrophy given as the ratio of the right ventricular (RV) and the left ventricular plus septum (LV+S) mass.
(G) Degree of muscularization of small pulmonary arteries. Data are given as percentages of total vessel count for fully muscularized (Full), partially muscularized
(Partial), and nonmuscularized (None) vessels.
(H) Representative histology from lung sections stained with hematoxylin and eosin (i, ii) or antibodies against a-smooth muscle actin (violet) or von Willebrand
factor (brown = endothelial cell marker; iii, iv). Themagnified histology of the alveolar structure in (i) and (ii) represents areas of emphysema formation, whereas (iii)
and (iv) depict the increase in the degree of muscularization indicated by violet color.
Data are mean ± standard error of the mean (SEM) from n = 6 lungs each in the time course of tobacco-smoke exposure for up to 8 months. *Significant
differences (p < 0.05) compared with unexposed controls (i.e., 0 months of exposure). See also Figure S1.confocal, and electronmicroscopy showed destruction of elastic
fibers during tobacco-smoke exposure and regeneration upon
curative L-NIL treatment (Figures 4B–4D and S4).
Cellular Components of PH and Emphysema
Development
A detailed fluorescence-activated cell sorter analysis performed
using the BAL and the remaining lung homogenate showed
a tendency toward increased numbers of granulocytes, macro-
phages, activated macrophages, CD4+ T cells (and CD8+ T cells,
but these were generally detected in very low numbers), and acti-vated T cells in the homogenate after 3 and 8 months of smoke
exposure. In the BAL, this trend only became evident for activated
granulocytes after 8 months of smoke exposure (Figure S3C). In-
terestingly, curative L-NIL treatment significantly downregulated
the number of granulocytes, macrophages, activated macro-
phages, and T cells (and also tended to activate T cells) in the
homogenate. In contrast, no such downregulation was detected
in theBAL (FigureS3C). Combinedquantification ofmacrophages
fromboth thealveolar andnonalveolar compartmentsby immuno-
histochemistry confirmed an upregulation of those cells and
a reduction upon curative L-NIL treatment (Figure S3D).Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 295
Figure 2. Localization and Relative Quantification of iNOS and eNOS in Wild-Type Mouse Lungs
(A) Immunostaining (i and ii; red) and nonisotopic in situ hybridization (iii and iv; green) for iNOS and eNOS in WT mouse lung sections. V = vessel, B = bronchus.
(B) Quantitative real-time polymerase chain reaction analysis for iNOS (i) and eNOS (ii) mRNA of small pulmonary vessels (outer diameter 50–100 mm), septa, and
bronchi (outer diameter 140–300 mm). iNOS and eNOS values were related to porphobilinogen deaminase mRNA levels. (i and ii) Data are from duplicate
measurements of n = 20 vessels from n = 3 lungs each.
(C)Western blot analysis of iNOS (i) and eNOS (ii) from lung homogenate, normalized to b-actin. Values are frommeasurements of n = 6 individual lungs each. Data
are given for 3 and 8 months of tobacco-smoke exposure and for unexposed controls (0 months). A representative blot is shown on the right and densitometry is
given on the left.
Data are presented as mean ± SEM. *Significant difference (p < 0.05) compared with unexposed controls (i.e., 0 months of exposure). See also Figure S2.To further decipher the role of iNOS in bone marrow (BM)-
derived versus non-BM-derived cells for the development of
emphysema and PH, we generated chimeric mice, where BM
from iNOS/ mice was transplanted into WT mice (iNOS//
WT) and vice versa (WT/iNOS/). WT-to-WT BM transplanta-
tion served as a control. Quantification of alveolar numbers by
stereology, in vivo hemodynamics and lung function, and
vascular morphometry showed that WT-to-WT transplanted
mice developed emphysema and PH after 4 months of smoke
exposure. Whereas the WT/iNOS/ mice were protected
from emphysema, iNOS//WT mice were not, as seen from
the changes in the number of alveoli as well as in vivo compliance
(Figures 5A and 5B). In contrast, only those chimeric mice with
deletion of iNOS in the BM cells were protected from vascular
alterations and PH (Figures 5C and 5D).296 Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc.Molecular Pathways Explaining Lung Emphysema
Development and Its Reversal upon Curative L-NIL
Treatment
ONOO is a possible candidate for mediating the effects of iNOS
upregulation on lung vasculature and parenchyma. As down-
stream signaling of ONOO can be mediated via nitrotyrosine
formation, we investigated nitrotyrosine levels in WT, eNOS/,
iNOS/, and L-NIL-treated mice, confirming a key role of
iNOS for nitrotyrosine formation (Figures 6A and S5A). We found
that ONOO indeed caused nitration in primary isolated alveolar
epithelial cells, pulmonary vascular endothelial cells, and pulmo-
nary arterial smooth muscle cells from resistance vessels (data
not shown). Subsequently, apoptosis was found to be induced
in epithelial and endothelial cells. Proliferation, however, was
only reduced in epithelial cells. No significant effect was found
Figure 3. Effects of Smoke Exposure in Mice Lacking iNOS or eNOS (iNOS/ or eNOS/) and in Wild-Type Mice Treated with an Inhibitor of
iNOS
(A–G) Comparison of iNOS/, eNOS/, and WT mice and (H–N) comparison of WT mice treated with L-NIL or placebo. Alveolar morphometry is given as
(A and H) mean linear intercept, (B and I) air space, and (C and J) septal wall thickness. (D and K) Right ventricular systolic pressure. (E and L) Ratio of number of
alveoli to the number of vessels per area. (F and M) Right-heart hypertrophy given as the ratio of the right ventricular (RV) and the left ventricular plus septum
(LV+S) mass. (G and N) Degree of muscularization of small pulmonary arteries (diameter 20–70 mm). Data are given as percentage of total vessel count for fully
muscularized (Full), partially muscularized (Partial), and nonmuscularized (None) vessels. Data are for n = 6 lungs each presented as mean ± SEM. *Significant
difference (p < 0.05) compared with placebo-treated mice. See also Figure S3.on apoptosis or proliferation in pulmonary arterial smooth
muscle cells (Figures 6B–6C). As a possible downstream link,
we investigated key mediators of proliferation and apoptosis,
like c-Jun N-terminal kinase (JNK), Src, and ERK phosphoryla-
tion. p-JNK was upregulated in alveolar epithelial and pulmonary
vascular endothelial cells (Figure 6D), but p-ERK and p-Src levels
were not affected by ONOO in any cell types investigated, and
JNK, ERK, and Src inhibitors could not antagonize ONOO
effects on proliferation and apoptosis (not shown). Investigation
of the effects of ONOO onRtp801 and VEGF formation revealed
that the Rtp801 protein was upregulated only in epithelial cells,
and VEGF was downregulated in epithelial and pulmonary arte-
rial smooth muscle cells (Figures 6E and 6F).
In addition, we addressed mechanisms of apoptosis, pro-
liferation, extracellular matrix destruction/restoration, oxidative
stress, and inflammation in small pulmonary artery vessels(diameter 50–100 mm), alveolar septa, and small bronchi (diam-
eter 140–300 mm; Figure S5B). This revealed that apoptosis
markers were consistently upregulated in the vascular compart-
ment by 3 months of smoke exposure, whereas no such upregu-
lation occurred in the alveolar septa. Importantly, this upregula-
tion of apoptosis markers in the vascular compartment was
strongly counter-regulated by curative L-NIL treatment, but no
such effects were seen in the alveolar or bronchial compart-
ments (Figure S5B). L-NIL treatment attenuated or reversed
the downregulation of the majority of the cell proliferation
markers (Figure S5B). This finding was supported by prolifer-
ating-cell nuclear antigen (PCNA) staining (Figure S5C). In addi-
tion, several genes found to be regulated by curative L-NIL
treatment for the categories of extracellular matrix regulation,
oxidative stress, and inflammation correlated with the restorative
effects of such treatment (Figure S5B).Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 297
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Figure 4. Pulmonary Effects of iNOS Inhibition in Wild-Type Mice following Chronic Smoke Exposure
(A) Total number of alveoli assessed by quantitative stereology (i), in vivo dynamic lung compliance (ii), and right ventricular systolic pressure (iii); n = 5 each.
(B) Quantification of elastin by determination of the amount of intact elastic fibers (i) and elastin score (ii) via light microscopy from paraffin-embedded lungs
(n = 5 each) or elastin content in cryopreserved lungs (iii) by confocal microscopy (CM) (n = 3).
(C) Representative slides of elastin-stained lungs from CM.
(D) Elastic fibers (*) magnified by electron microscopy.
Data are presented as mean ± SEM. *Significant difference (p < 0.05) between groups as indicated. See also Figure S4.With regard to ONOO generation, we used lung homoge-
nates (deprived of alveolar leukocytes) versus BAL cells to
assess the activity of iNOS and O2
, generation in different
lung compartments. NO levels derived from iNOS were in-
creased in the homogenized lungs, reflecting iNOS upregula-
tion. Conversely, NO levels from BAL cells were unchanged
related to a per-cell basis (Figures S2A and S2B). The increase
in iNOS-derived NO from emphysematous lungs was reversed
by curative L-NIL treatment but not by placebo (Figure S2A).
Determination of O2
, generation from homogenized lung
tissue and from BAL cells revealed no alteration in levels
during the course of the disease or upon treatment in the
lung homogenate (when normalized to the amount of protein
or alveolar macrophages and related on a per-cell basis)
(Figure S2C).298 Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc.Comparison of Human End-Stage COPD in Smokers
to a Mouse Model of Emphysema Induced
by Tobacco Smoke
When comparing lung tissue from patients with Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stage IV COPD
(Rabe et al., 2007) and a history of smoking (Table S1) to that
of healthy donors, we found a similar increase in mean linear
intercept and air space measures and a similar decrease in
septal wall thickness (Figures 7A–7C and 7F) as seen in WT
mice after 8 months of tobacco-smoke exposure. In addition,
similar to mice, an increase in the ratio of the number of alveoli
to the number of vessels and an increased degree of vessel mus-
cularization were found in the tissue samples from patients with
COPD (Figures 7D–7F) compared to healthy donors. Smokers
who had not yet developed COPD displayed similar vascular
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Figure 5. Pulmonary Effects of Smoke Exposure in Bone Marrow-Transplanted, iNOS/ Chimeric Mice
(A–C) Total number of alveoli assessed by (A) quantitative stereology (n = 8), (B) in vivo dynamic lung compliance (nR 9), and (C) hemodynamics (nR 9).
(D) Quantification of degree of muscularization of small pulmonary arteries (diameter 20–70 mm) as percent of total vessel count for fully muscularized (Full),
partially muscularized (Partial), and nonmuscularized (None) vessels (nR 9 for each).
Data are given as mean ± SEM for chimeric mice with BM transplantation fromWT to WTmice (WT/WT), WT to iNOS/mice (WT/iNOS/), and iNOS/ to
WT (iNOS//WT) mice. *Significant difference (p < 0.05) as indicated.alterations to those observed in smokers suffering from COPD
(Figures 7A–7E). Analysis of iNOS and eNOS expression in
human lung tissue also showed a similar pattern of regulation
in the COPD lungs and in those of donor controls as in smoke-
exposed and control mice. In circumstances where iNOS was
upregulated in the pulmonary vasculature, eNOS was down-
regulated (Figures 7G and 7H). Levels of nitrotyrosine protein in
the pulmonary vasculature and alveoli were increased in
samples from patients with COPD compared with donor controls
(Figure 7I). Again, similar regulation profiles were found in
smokers without COPD.
DISCUSSION
We sought to determine whether the vascular pathology is
linked to emphysema development and identified iNOS as
a key molecular player in the underlying processes. Our data
showed that alterations in lung vascular structure and function
induced by tobacco smoke preceded emphysema in mice
and were independent of hypoxia. We also showed that emphy-sema and PH occurred independently and are essentially asso-
ciated with iNOS in different cell types. Finally, our data indicate
that targeting iNOS by pharmacological inhibition can improve
the functional and structural destruction caused by tobacco
smoke.
Long-term exposure to tobacco smoke in our mouse model
enabled analysis of the temporal order of structural and func-
tional changes in both the pulmonary vasculature and the
airways and alveolar structures during the development of lung
emphysema. The development of lung emphysema in our model
correlated with previous reports that used mice exposed to
tobacco smoke (Churg et al., 2008). Vascular remodeling upon
tobacco-smoke exposure has been shown in humans (Peinado
et al., 2008) and in animal models (Ferrer et al., 2009; Wright
and Churg, 1991;Wright et al., 2006, 2011); however, we provide
here a detailed direct comparison of alterations in vascular struc-
ture and function and their temporal relationship to alveolar
destruction in mice. In this regard, dysregulation of iNOS and ni-
trotyrosine formation have been proposed as underlying mech-
anisms of COPD (Brindicci et al., 2009).Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 299
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Figure 6. Nitrotyrosine Expression in Lungs of iNOS/ and eNOS/ and L-NIL-TreatedWild-TypeMice andEffects of Peroxynitrite (ONOO)
on Cell Growth and Apoptosis
(A) Western blot analysis of nitrotyrosine from homogenized lung tissue in WT, iNOS/, eNOS/, and L-NIL-treated WT mice (preventive approach; n = 4 for
each).
(B and C) Assessment of (B) apoptosis and (C) proliferation in AECII, microvascular EC, and PASMC after treatment with ONOO or KOH (control) for 20 min.
Staurosporine (stau) was used as a positive control for apoptosis. Values are normalized to controls and derived from n = 3 (AECII), n = 4 (EC) and n = 6–8 (PASMC)
independent experiments.
(D)Western blot analysis of phospho(p)-JNK fromAECII, EC, and PASMC after ONOO incubation for 5min. Data are normalized to respective unphosphorylated
protein (n = 7 [AECII], n = 9 [EC], or n = 3 [PASMC] independent experiments).
(E)Western blot analysis of Rtp801 fromAECII, EC, and PASMCafter ONOO and inhibitor incubation. Data are normalized to b-actin (n = 3 [AECII and EC] or n = 5
[PASMC] independent experiments).
(F) VEGF concentration in AECII, EC, and PASMC after ONOO and inhibitor incubation by ELISA. Values are normalized to controls and derived from n = 4
(AECII), n = 3 (EC), and n = 8 (PASMC) independent experiments and are given as mean ± SEM.
*Significant difference (p < 0.05) compared with controls or between L-NIL-treated and untreated mice. See also Figure S5.Our investigations of the cellular contribution to both emphy-
sema development and PH in chimeric mice showed that both
can occur independently. The complete dependency of pulmo-
nary vascular alterations on BM-derived iNOS-containing cells
can be explained by a derivation of a portion of pulmonary
vascular cells from BM cells. It has been suggested that BM-
derived cells contribute to pulmonary vascular remodeling, and
that pulmonary arterial smooth muscle cells may be generated
from BM-derived cells (Asosingh et al., 2008; Huertas and Pal-
ange, 2011). Indeed, the importance of BM cell-derived iNOS300 Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc.for induction of systemic vascular disease was highlighted
recently by Ponnuswamy and colleagues (Ponnuswamy et al.,
2009). Alternatively, iNOS from non-smoothmuscle, BM-derived
cells could contribute also to pulmonary vascular remodeling.
The fact that emphysema was only prevented in chimeric mice
that lacked iNOS in non-BM-derived cells excludes an essential
role for iNOS in the pathogenesis of emphysema in macro-
phages or other BM-derived cells. This supports the concept
of a prominent role of non-BM-cell-derived iNOS and thus,
e.g., vascular iNOS for emphysema development. Interestingly,
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Figure 7. Comparison of the Alveolar and Vascular Structure, eNOS and iNOS Expression, and Nitrotyrosine Formation in Lungs fromHuman
Patients with Severe COPD, Smokers without COPD, and Healthy Donor Controls
(A–C) Alveolar morphometry given as (A) mean linear intercept, (B) air space, (C) septal wall thickness.
(D) Ratio of the number of alveoli to the number of vessels.
(E) Degree of muscularization of small pulmonary arteries (diameter 20–70 mm). Data are given as percentage of total vessel count for fully muscularized (Full),
partially muscularized (Partial), and nonmuscularized (None) vessels.
(F) Representative histology from stained lung sections, representing alveolar changes (i) or antibodies against a-smooth muscle actin (violet) and vonWillebrand
factor (brown = endothelial cell marker) (ii).
(G) iNOS (i) and eNOS (ii) immunostaining. V = vessel.
(H) Expression of iNOS mRNA (i), iNOS protein (ii), eNOS mRNA (iii), and eNOS protein (iv).
(I) Densitometric data from a western blot analysis of nitrotyrosine from homogenized lung tissue.
*Significant difference (p < 0.05) compared with healthy donor controls. Data are derived from human GOLD stage IV COPD lungs (smoker+COPD), smokers
without COPD (smokerCOPD), and healthy donor control lungs (donor) and are presented as mean ± SEM. See also Table S1.the data from the chimeric mice further suggested that emphy-
sema development can be dependent on vascular iNOS in the
absence of vascular remodeling. The fact that emphysema
development and PH in the chimeric mice were triggered by
different cell populations and, thus, can occur independently
may explain why only a portion of patients suffering from
COPDdevelop PH (if themice data are transferable to the human
situation).
The increased levels of nitrotyrosine, present as a possible
consequence of ONOO generation (Szabo´ et al., 2007), in WT
mice following tobacco-smoke exposure were in accordancewith our hypothesis that ONOO upregulation is a key step in
vascular remodeling and emphysema pathogenesis. Interest-
ingly, ONOO both induced apoptosis and reduced proliferation
in alveolar epithelial cells but caused only apoptosis in endothe-
lial cells. This result agreed with the observed effects on alveolar
and vascular pruning in our animal studies. Such effects of
ONOO are also concordant with previous findings of apoptosis
induction (Szabo´ et al., 2007), a mechanism important for the
development of lung emphysema (Yoshida and Tuder, 2007).
We have shown that ONOO can induce JNK but not ERK
and Src phosphorylation; however, such effects could not beCell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 301
associated with proliferation or apoptosis by respective inhibitor
studies. Interestingly, ONOO upregulated Rtp801, a protein
identified as essential for emphysema development in mice
(Yoshidaet al., 2010), in alveolar epithelial cellsbut not endothelial
or vascular smoothmuscle cells. Such a regulation has been sug-
gested to involvedownstreamVEGF inhibition, leading toalveolar
epithelial cell apoptosis (Ellisen, 2010;Yoshidaet al., 2010).VEGF
geneknockout causesemphysema inmice (Taraseviciene-Stew-
art and Voelkel, 2008), and VEGF has been shown to be essential
for lung growth and maintenance (Voelkel et al., 2006). In accor-
dance, we showed downregulation of VEGF in alveolar epithelial
type II cells (AECII) andprimarymurinepulmonary arterial smooth
muscle cells (PASMC) upon ONOO challenge.
Analyzing gene-regulatory processes upon curative L-NIL
treatment revealed several candidates that can be linked to
lung regeneration or support regeneration by attenuation of dis-
ease progression. L-NIL reversed the upregulation of Mmp9 (a
marker of parenchyma destruction), and the mRNA of the
metalloproteinase inhibitor encoded by Timp3 was upregulated
in the vascular compartment with L-NIL treatment. It has previ-
ously been shown that Timp3 knockout mice develop emphy-
sema (Leco et al., 2001). The reversal of the mRNA downregula-
tion of pro-proliferative factors like Fgf10 and Ccna1 in alveolar
septa by curative L-NIL treatment correlates with the increase
in PCNA-positive cells. Corroborating these findings, the upre-
gulation of mRNA of proapoptotic genes Bax, Tnfsf10, Fbf1,
Traf1, and Fastk in the vascular compartment was again antago-
nized by curative L-NIL treatment.
Our detailed analysis of the elastic fiber structure of the lung
supports the concept that the increase in proliferation upon
curative L-NIL treatment is part of an active restructuring pro-
cess of the lung. Different methods of quantification and ultrafine
structural images revealed that the amount, as well as the struc-
ture, of elastin fibers is reduced and degraded, respectively,
during tobacco-smoke exposure and is substantially reversed
upon curative L-NIL treatment.
Interestingly, curative L-NIL treatment selectively reduced the
number of granulocytes, macrophages, activatedmacrophages,
and T cells in the lung-tissue compartment. Downregulation of
macrophage numbers may coincide with reduced O2
, produc-
tion, leading to decreased oxidative stress and thus reduced
ONOO levels, but also to reduced inflammatory mediator levels
(Chung and Adcock, 2008). In addition, the observed downregu-
lation of T cells correlates with the hypothesis that autoimmune
mechanisms may contribute to COPD development (Churg
et al., 2008; Feghali-Bostwick et al., 2008; Motz et al., 2010).
Moreover, it is suggested that T cells are involved not only in
emphysema development but also in the pathological remodel-
ing of the pulmonary vasculature (Austin et al., 2010; Cuttica
et al., 2011). As our data from the chimeric mice show that
the entire vascular remodeling process is dependent on BM-
derived iNOS-expressing cells, this effect could be due either
to inflammatory cells like macrophages or to iNOS-containing
stem cells. Moreover, data from our experiments performed
in chimeric mice showed that emphysema development can
be independent on iNOS in BM-derived cells and, thus, is at least
independent from iNOS in macrophages, activated macro-
phages, granulocytes, T cells, and activated T cells.302 Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc.Examination of lung tissue from ten patients with severe COPD
(GOLD stage IV) who had undergone lung transplantation re-
vealed an upregulation of iNOS (mRNA and protein), increases
in nitrotyrosine content, and alterations in vascular and alveolar
structure and function qualitatively similar to those seen in the
smoke-exposed WT mice. In addition, we have corroborated
previous findings in lung-tissue samples from smokers who
had not developed COPD, demonstrating vascular alterations
in direct association with tobacco-smoke exposure (Peinado
et al., 2008). The similar profiles of iNOS and nitrotyrosine regu-
lation in smokers with COPD and smokers who had not devel-
oped COPD suggest that portions of the pathways deciphered
in our mouse model also may have an impact on human
COPD; however, this conclusion has to be drawn cautiously,
as our data are for a limited number of patients, are for end-stage
COPD, and are heterogeneous in nature when compared
with the mouse lung data. In addition, a confounding impact of
hypoxia or treatment including steroids should be taken into
account when applying the mouse data to the human situation.
If iNOS inhibition is to be investigated further as a clinical means
of treatment for emphysema, one has to consider possible
side effects related to disruption of iNOS function. As iNOS is
expressed in many cell types, including nonimmune cells and
immune cells (Bogdan, 2001), several cellular and systemic,
including immune, functions may be disrupted by iNOS inhibi-
tion. However, to date, no adverse effects concerning increased
susceptibility to infections have been reported in clinical studies
with selective iNOS inhibitors (Brindicci et al., 2009; Singh et al.,
2007). Owing to its effects on T cell regulation, it has been sug-
gested that abrogation of iNOS function could potentially exac-
erbate autoimmune diseases such as colitis, arthritis, or multiple
sclerosis (Niedbala et al., 2007). There are also implications for
iNOS playing a role in systemic vascular disease, and this has
been assessed in animal models including atherosclerosis (Pon-
nuswamy et al., 2009). Thus, given the potentially wide-ranging
effects of iNOS inhibition, any clinical intervention for emphy-
sema may require local application of iNOS inhibitors via inhala-
tion or cell-type-specific targeting of iNOS inhibition.
In conclusion, our study highlights that the effects of tobacco
smoke on the pulmonary circulation precede the development
of alveolar destruction and emphysema formation, and both
vascular and alveolar changes occur in an iNOS-dependent
manner in mice. Furthermore, emphysema and PH development
are not essentially linked but can occur independently. If trans-
ferable to humans, these findings could explain the hitherto
controversial discussion about the impact of PH on emphysema
development in humans, where PH is not always associated with
emphysema. Finally, we suggest that selective iNOS inhibition
offers the potential to reverse emphysema.
EXPERIMENTAL PROCEDURES
Animals
Adult male WT C57BL/6J, iNOS/, and eNOS/ (B6.129P2-Nos2tm1Lau/J
and B6.129P2-Nos3tm1Unc/J) mice, 20–22 g, were obtained from Charles
River Laboratories, Sulzfeld, Germany. Animals were housed under con-
trolled conditions with a 12 hr light/dark cycle and food and water supply
ad libitum. Animals were randomly allocated to tobacco-smoke-exposed
and -unexposed groups of six mice each, with parallel groups for (1) alveolar
morphometry, (2) vascular morphometry including right ventricular blood-
pressure measurements, (3) protein and mRNA analysis, and (4) lung-function
tests. Selected parameters of alveolar and vascular structural and functional
measurements were assessed in a separate, independent set of experiments.
All experiments were approved by the governmental ethics committee for
animal welfare (Regierungspra¨sidium Giessen, Germany).
Experimental Design and Tobacco-Smoke Exposure
Wild-type, eNOS/, and iNOS/ mice were exposed to mainstream smoke
of 3R4F cigarettes (Lexington, KY, USA) at 140 mg particulate matter/m3 for
6 hr/day, 5 days/week for up to 8 months. For preventive treatment, WT
mice were exposed to tobacco smoke for 8 months with parallel application
of the iNOS inhibitor L-NIL (N6-(1-Iminoethyl)-L-lysine dihydrochloride) (Bio-
tium, Hayward, CA, USA) at a concentration (600 mg/ml = 2.68 mM) known
to be highly iNOS selective in drinking water (Moore et al., 1994; Stenger
et al., 1995). Age-matched controls were kept under identical conditions to
the smoke-exposed mice but without smoke exposure. Very few of the para-
meters measured in this study were affected by the age of the control mice.
Therefore, the 8 month control values are given as control values if there
was no age effect.
In the curative approach, L-NIL treatment (2.68 mM in drinking water) was
started in WT mice after full establishment of the disease (8 months
tobacco-smoke exposure) for 3 months without further smoke exposure.
Age-matched, non-smoke-exposed mice and placebo-treated smoke-
exposed mice were used as controls. The drinking water for placebo was
adjusted to the same pH as the L-NIL solution. Each day, freshly prepared
L-NIL and placebo solutions were supplied to the animals. Tobacco-smoke
exposure was discontinued in the last 3 month treatment period. The curative
approach was performed in two independent sets of experiments.
Animal Preparation, In Vivo Hemodynamics, Alveolar and Vascular
Morphometry, Right-Heart Hypertrophy, and Lung Compliance
All animals were anesthetized with ketamine and xylazine and treated with
heparin (1000 U/kg) at the end of the experiments. Measurement of right-
ventricular systolic pressure (RVSP) was performed as described previously
(Schermuly et al., 2005). For alveolar morphometry, lungs were fixed by instil-
lation of paraformaldehyde via the trachea. For vascular morphometry and
determination of the alveoli to vessel ratio, lungs were fixed by vascular perfu-
sion with Zamboni’s fixative. The degree of muscularization was determined
from stained lung sections as described previously (Weissmann et al., 2006).
For right-heart hypertrophy, the right ventricle (RV) was separated from the
left ventricle plus septum (LV+S), and the RV to (LV+S) ratio was determined
from the dried tissue. In vivo dynamic lung compliance was assessed prior
to RVSP measurement. (For further details see Extended Experimental
Procedures online).
Isolated, Perfused Mouse Lung Experiments
For measurement of lung-function parameters, except those in Figures 4
and 5, an isolated, perfused mouse lung procedure was used as described
previously (Weissmann et al., 2006). For details, refer to Extended
Experimental Procedures online.
Isolation and Culture of Primary Murine Lung Cells, Exposure to
ONOO, and Quantification of Proliferation and Apoptosis
PASMC, lung endothelial cells (EC), and AECII were isolated from WT mice
and cultured as described previously (Corti et al., 1996; Mittal et al., 2007;
Weissmann et al., 2006). For details, refer to Extended Experimental
Procedures online.
ONOO was applied as described previously (Potoka et al., 2003). In brief,
the cells were washed with Dulbecco’s Phosphate-buffered Saline (DPBS,
Sigma-Aldrich, Steinheim, Germany), and ONOO (50 mM; Alexis Biochemi-
cals, San Diego, CA, USA) or potassium hydroxide (as a control; Merck, Darm-
stadt, Germany) was mixed into the solution. For the proliferation and
apoptosis assay, cells were cultured in serum-free medium overnight prior
to ONOO application.
Proliferation assay was performed as described previously (Mittal et al.,
2007). After incubation with ONOO, the culture medium was replaced withregular medium, containing serum and [3H]thymidine (Amersham, Munich,
Germany). After incubation at 37C and 5% CO2 for 4 hr, cells were harvested
and [3H]thymidine incorporation was measured by liquid scintillation
spectrometry.
For assessment of apoptosis, the CaspACE Assay System, Colorimetric
(Promega, Mannheim, Germany), was used according to the manufacturer’s
instructions. Additionally, 1 mM staurosporine (Sigma-Aldrich, Munich,
Germany) for 4 hr was used as a positive control.
VEGF-ELISA
For detection of VEGF in cell culture medium, the RayBio Mouse VEGF ELISA
Kit (RayBiotech, Inc.) was used. Experiments were performed according to
the protocol provided by the supplier.
Generation of Bone Marrow-Transplanted Chimeric Mice
Generation of chimeric mice was performed as previously described
(Voswinckel et al., 2003) with modifications. For details, refer to Extended
Experimental Procedures online.
Alveoli Count via Design-Based Stereology
For counting of alveoli, uniform random sampling and the physical dissector
method were used as described previously (Ochs et al., 2004). For details,
refer to Extended Experimental Procedures online.
Localization of eNOS, iNOS, and Nitrotyrosine
Localization of eNOS and iNOS was investigated in lung sections from cryo-
preserved tissue by immunostaining, as described previously (Mittal et al.,
2007). Nitrotyrosine was detected in paraffin-embedded lung sections of
both mouse and human lung tissue using a rabbit anti-nitrotyrosine antibody
(Sigma-Aldrich). For details, refer to Extended Experimental Procedures
online.
PCNA Staining
For immunohistochemical localization of the proliferation marker PCNA
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), the AP-fast red kit
(Zytochem, Berlin, Germany) was used on paraffin-embedded lung sections
according to the manufacturer’s instructions. All stained sections were
analyzed using digital slide scanning employing a mirax scanner and the mirax
viewer software (Carl Zeiss GmbH, Jena, Germany).
Nonisotopic In Situ Hybridization
Localization of mRNA by nonisotropic in situ hybridization (NISH) was deter-
mined in cryostat lung sections as previously described (Mittal et al., 2007).
For details, refer to Extended Experimental Procedures online.
Laser-Assisted Microdissection
Laser-assisted microdissection (LMD 6000, Leica, Nussloch, Germany) was
performed to isolate pulmonary arterial vessels, bronchi, and septa from cryo-
stat lung section as previously described (Mittal et al., 2007). For details, refer
to Extended Experimental Procedures online.
RNA Isolation, Preamplification, cDNA Synthesis,
and Real-Time PCR
RNA from laser-microdissected or homogenized mouse and human lung
tissue was isolated by RNeasy Micro and Mini kits, respectively (QIAGEN,
Hilden, Germany). The isolated RNA was converted to cDNA, and relative
quantification of the eNOS and iNOS mRNA was performed using the iQ
SYBR Green Supermix (BioRad, Munich, Germany). For details, refer to
Extended Experimental Procedures online.
Real-Time PCR-Based PCR Array
Vessels (diameter 50–100 mm), septa, and bronchi (diameter 140–300 mm)
were laser-microdissected from 8 mm sections of Tissue Tek-embedded
mouse lungs fixed after BAL. PCR-based arrays were performed using
customized 96-well plates containing primers for selected genes, according
to the manufacturer’s instructions (SA Biosciences/Biomol, Hamburg,
Germany).Cell 147, 293–305, October 14, 2011 ª2011 Elsevier Inc. 303
Western Blot
For the quantification of eNOS, iNOS, and nitrotyrosine in mouse and human
lung tissues, the polyclonal antibodies anti-eNOS (BD Biosciences, Heidel-
berg, Germany), or anti-iNOS (Abcam, Cambridge, UK), raised in rabbits,
and anti-nitrotyrosine (Abcam, Cambridge, UK), raised in mice, were used.
For the quantification of (phospho)-SAPK/JNK, (phospho)-ERK (both Cell
Signaling, Danvers, MA, USA), (phospho)-Src (Epitomics, Burlingame, CA,
USA), and Rtp801 (Abnova, Heidelberg, Germany) in mouse PASMC, EC,
and AECII, the respective polyclonal antibodies raised in rabbits were used.
For details, refer to Extended Experimental Procedures online.Quantification of Lung Elastin by Image Analysis
Analysis was performed as previously published with modifications (Bigatel
et al., 1999; Black et al., 2008; Lawrence et al., 2004). For details, refer to
Extended Experimental Procedures online.Confocal Microscopy and Quantification of Elastin Immunolabeling
Experiments were performed on cryosections of 30 mm thickness using
specific antibodies against elastin and a-smooth muscle actin. For details,
refer to Extended Experimental Procedures online.Transmission Electron Microscopy
The tissue was fixed in 3% glutaraldehyde and embedded in Epon following
routine procedures. Ultrathin sections were double stained with uranyl acetate
and lead citrate and viewed in a Philips CM 10 or a CM 201 electron
microscope (Philips, Andover, MA, USA).Patient Characteristics
Human lung tissues were obtained from transplanted COPD patients (GOLD
stage IV), smokers without COPD, and donor controls. The patients’ charac-
teristics are given in Table S1. The studies were approved by the Ethics
Committee of the Justus-Liebig-University School of Medicine (AZ 31/93),
Giessen, Germany.
For all other experimental procedures, please refer to the Extended
Experimental Procedures online.Statistical Analyses
Comparison of multiple groups was performed by analysis of variance
(ANOVA) with the Student–Newman–Keuls post-test. If several groups were
compared to one control, an ANOVA with Dunnett’s test was performed. For
comparison of two groups, a Student’s t test was performed. We considered
p values below 0.05 as statistically significant for all analyses.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at doi:10.
1016/j.cell.2011.08.035.ACKNOWLEDGMENTS
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